||MSH2 Full Gene Sequencing
#ExistInterpData>Background Information for HNPCC/Lynch syndrome (MSH2) Sequencing and Deletion/Duplication:
Characteristics: Increased risk of colorectal and extra-colonic cancers including endometrial, renal pelvis, ureter, ovary, stomach, small intestine, and hepatobiliary tract.
Incidence: 1-2 percent of colorectal cancer is due to mismatch repair gene mutations.
Inheritance: Autosomal dominant
Penetrance: 80 percent lifetime risk of colorectal cancer; 20-60 percent risk for endometrial cancer.
Cause: Pathogenic Germline MLH1, MSH2, MSH6, and PMS2 gene mutations.
Gene tested: MSH2
Clinical Sensitivity: 40 percent of Lynch syndrome cases are due to MSH2 mutations
Methodology: Bidirectional sequencing of MSH2 coding regions and intron-exon boundaries; multiplex ligation-dependent probe amplification (MLPA) to detect large MSH2 exonic deletions and EPCAM (TACSTD1) exon 9 deletions.
Analytical Sensitivity & Specificity: 99 percent.
Test Limitations: Rare diagnostic errors can occur due to primer and probe site mutations. The breakpoints of large deletions/duplications will not be determined. Regulatory region mutations, deep intronic mutations and mutations in genes other than MSH2 will not be detected.
This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.
See Compliance Statement C: www.aruplab.com/CS
||Lynch Syndrome (HNPCC/Lynch Syndrome (MSH2) Sequencing and Deletion/Duplication)
, MSH2 (HNPCC/Lynch Syndrome (MSH2) Sequencing and Deletion/Duplication)